114 East 4th Avenue
Vancouver, BC V5T 1G4
Full-time employees: 455
|Mr. Neil A. Klompas C.A., CPA, CA, CPA||Chief Operating Officer||589.86k||N/A||1972|
|Dr. Ali Tehrani Ph.D.||Advisor||877.66k||N/A||1972|
|Mr. Kenneth H. Galbraith C.A.||Pres, CEO & Chairman||N/A||N/A||1963|
|Mr. Chris Astle Ph.D.||Sr. VP & CFO||N/A||N/A||N/A|
|Jack W. Spinks||Mang. of Investor Relations||N/A||N/A||N/A|
|Mr. Daniel Dex J.D., Ph.D.||VP of Legal & Corp. Sec.||N/A||N/A||N/A|
|Mr. Mark Hollywood||Sr. VP of Technical & Manufacturing Operations||N/A||N/A||1970|
|Dr. Bruce Hart Ph.D.||Sr. VP of Regulatory||N/A||N/A||N/A|
|Dr. Neil Josephson M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Dr. David Poon Ph.D.||VP of Bus. Devel. and Alliance Management||N/A||N/A||N/A|
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.